Edition:
United States

Citius Pharmaceuticals Inc (CTXR.OQ)

CTXR.OQ on NASDAQ Stock Exchange Capital Market

3.78USD
16 Feb 2018
Change (% chg)

$0.30 (+8.62%)
Prev Close
$3.48
Open
$3.49
Day's High
$3.79
Day's Low
$3.49
Volume
13,179
Avg. Vol
22,705
52-wk High
$5.46
52-wk Low
$0.34

Latest Key Developments (Source: Significant Developments)

Citius Announces $6 Mln Registered Direct Offering Priced At-The-Market
Monday, 18 Dec 2017 08:00am EST 

Dec 18 (Reuters) - Citius Pharmaceuticals Inc ::CITIUS ANNOUNCES $6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET.CITIUS PHARMACEUTICALS - ENTERED AGREEMENTS WITH SEVERAL INSTITUTIONAL, ACCREDITED INVESTORS TO BUY 1.3 MILLION SHARES AT $4.6925/SHARE.  Full Article

Citius Pharmaceuticals Says On Nov 27, Board Appointed Jaime Bartushak As CFO And Principal Financial Officer Of Co
Friday, 1 Dec 2017 05:14pm EST 

Dec 1 (Reuters) - Citius Pharmaceuticals Inc ::CITIUS PHARMACEUTICALS INC - ‍ON NOV 27, , BOARD APPOINTED JAIME BARTUSHAK AS CFO AND PRINCIPAL FINANCIAL OFFICER OF COMPANY, EFFECTIVE NOV. 27, 2017​.  Full Article

Citius Pharmaceuticals files for mixed shelf offering of up to $50 mln - SEC filing‍​
Thursday, 9 Nov 2017 05:46pm EST 

Nov 9 (Reuters) - Citius Pharmaceuticals Inc :Citius Pharmaceuticals Inc - files for mixed shelf offering of up to $50 million - SEC filing‍​.  Full Article

Citius pharmaceuticals receives "fast track" designation by FDA for mino-lok™ investigational trial
Tuesday, 31 Oct 2017 08:00am EDT 

Oct 31 (Reuters) - Citius Pharmaceuticals Inc :Citius Pharmaceuticals, Inc. Receives "fast track" designation by FDA for mino-lok™ investigational trial.  Full Article

Citius Pharmaceuticals provides phase 3 update on Mino-Lok clinical trial following FDA meeting
Tuesday, 5 Sep 2017 07:00am EDT 

Sept 5 (Reuters) - Citius Pharmaceuticals Inc ::Citius Pharmaceuticals, Inc provides phase 3 update on Mino-Lok™ clinical trial following FDA meeting.Citius Pharmaceuticals, Inc. Provides phase 3 update on mino-lok™ clinical trial following FDA meeting.Citius Pharmaceuticals Inc - ‍citius is currently recruiting sites for a phase 3 trial of Mino-Lok in United States​.Citius Pharmaceuticals Inc - ‍received feedback from u. s. Food and drug administration regarding amendments to phase 3 study plan for Mino-Lok​.Citius pharmaceuticals inc - ‍following discussion with FDA, Citius amended phase 3 study design to remove saline and heparin placebo control arm​.Citius Pharmaceuticals Inc - ‍fda agreed that an open label, superiority design would address company's concerns and would be acceptable for Mino-Lok​.  Full Article